Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.84)
# 3,710
Out of 4,843 analysts
48
Total ratings
22.86%
Success rate
-25.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $18.78 | - | 2 | Apr 23, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $5.53 | - | 4 | Apr 1, 2025 | |
| GLYC GlycoMimetics | Initiates: Overweight | n/a | $0.21 | - | 1 | Mar 21, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $3.52 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $9.14 | +42.34% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $2.86 | - | 2 | Mar 7, 2025 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $4.58 | - | 1 | Feb 21, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $35.75 | - | 4 | Feb 19, 2025 | |
| CDTX Cidara Therapeutics | Assumes: Overweight | n/a | $21.72 | - | 1 | Jan 27, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $65.07 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.07 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.20 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $96 | $30.72 | +212.50% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $4.97 | - | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.11 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $130.56 | +123.65% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $441.83 | -16.26% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.73 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.28 | - | 1 | May 30, 2017 |
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.78
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.53
Upside: -
GlycoMimetics
Mar 21, 2025
Initiates: Overweight
Price Target: n/a
Current: $0.21
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.52
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $9.14
Upside: +42.34%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.86
Upside: -
Prothena Corporation
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.58
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $35.75
Upside: -
Cidara Therapeutics
Jan 27, 2025
Assumes: Overweight
Price Target: n/a
Current: $21.72
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $65.07
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.07
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.20
Upside: -
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $30.72
Upside: +212.50%
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.97
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.11
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $130.56
Upside: +123.65%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $441.83
Upside: -16.26%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.73
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.28
Upside: -